Atrion (ATRI) Upgraded to Buy by BidaskClub

Atrion (NASDAQ:ATRI) was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating in a research report issued on Saturday.

Shares of Atrion stock opened at $680.60 on Friday. Atrion has a twelve month low of $516.85 and a twelve month high of $718.11. The stock has a market cap of $1.29 billion, a PE ratio of 38.15 and a beta of 0.56.

Atrion (NASDAQ:ATRI) last issued its earnings results on Tuesday, August 7th. The medical instruments supplier reported $4.70 earnings per share for the quarter. Atrion had a net margin of 22.57% and a return on equity of 17.99%. The business had revenue of $38.85 million for the quarter.

Several institutional investors have recently modified their holdings of the company. Denali Advisors LLC boosted its position in shares of Atrion by 65.4% during the 3rd quarter. Denali Advisors LLC now owns 3,805 shares of the medical instruments supplier’s stock valued at $2,644,000 after acquiring an additional 1,505 shares in the last quarter. Schroder Investment Management Group boosted its position in shares of Atrion by 11.7% during the 2nd quarter. Schroder Investment Management Group now owns 1,033 shares of the medical instruments supplier’s stock valued at $619,000 after acquiring an additional 108 shares in the last quarter. WINTON GROUP Ltd acquired a new stake in shares of Atrion during the 2nd quarter valued at about $396,000. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp acquired a new stake in shares of Atrion during the 2nd quarter valued at about $240,000. Finally, Renaissance Technologies LLC boosted its position in shares of Atrion by 11.2% during the 2nd quarter. Renaissance Technologies LLC now owns 69,500 shares of the medical instruments supplier’s stock valued at $41,658,000 after acquiring an additional 7,000 shares in the last quarter. Institutional investors and hedge funds own 61.11% of the company’s stock.

About Atrion

Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.

Read More: Stock Symbols, CUSIP and Other Stock Identifiers

Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply